The research conducted by FRITZ et al. provided additional confirmation that pharmacological inhibition of SCD1 activity reduces lipid synthesis, inhibits the growth of androgen-sensitive and androgen-resistant prostate cancer cells, stops the growth of prostate tumor xenografts in nude mice, and improves survival in nude mice [168]. This evidence concerns the gene SCD and prostate carcinoma.